Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

hearing loss

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

Study reveals two copies of APOE4 gene could increase risk of developing Alzheimer’s

The progressive neurodegenerative disease is the most common form of dementia

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Study reveals early menopause and higher CVD risk could be linked to cognitive decline

Approximately 733,040 people in Canada are estimated to be living with dementia

- PMLiVE

Two UK clinical trials launched to identify blood tests for dementia diagnosis

The neurodegenerative condition affects more than 944,000 people in the UK

- PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

The progressive neurodegenerative disease affects around ten million people worldwide

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s

The study found that men prescribed PDE5Is were 18% less likely to develop the disease

Biogen Idec building

Biogen to discontinue Alzheimer’s drug Aduhelm in favour of Eisai-partnered Leqembi

The post-marketing confirmatory study of the intravenous treatment will now be terminated

- PMLiVE

UK government announces nearly £50m to expand dementia research sites

The funding will be used to enable more people to take part in clinical trials for dementia

- PMLiVE

Study suggests hearing aids could prevent onset and progression of dementia

People with severe hearing loss had an increased risk of up to 20% of developing dementia

- PMLiVE

Researchers develop new blood test to identify risk of Parkinson’s disease

The findings could help to identify people most likely to benefit from disease-modifying therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links